硕世生物(688399) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥90,639,768.40, representing a year-on-year increase of 0.92%[2]. - The net profit attributable to shareholders for the same period was -¥2,125,862.61, while the net profit for the year-to-date period increased by 115.40% to ¥27,114,657.29[2][7]. - The net profit for Q3 2024 was CNY 27,114,657.29, a significant recovery from a net loss of CNY 176,014,301.45 in the same period last year, marking a turnaround of over 115%[17]. - Operating profit for Q3 2024 reached CNY 33,048,345.37, compared to an operating loss of CNY 161,635,365.05 in Q3 2023, indicating a substantial improvement[17]. - The total profit for Q3 2024 was CNY 32,237,455.29, a significant recovery from a total loss of CNY -164,302,028.83 in Q3 2023[17]. - The company reported a net profit of CNY 2,537,690,516.95, slightly up from CNY 2,510,575,859.66, indicating a growth of about 1.1%[16]. Research and Development - Research and development (R&D) expenses totaled ¥25,913,873.43 in Q3 2024, a decrease of 14.03% compared to the same period last year, accounting for 28.59% of operating revenue[3]. - Research and development expenses for the first three quarters of 2024 were CNY 72,683,955.39, down from CNY 98,908,502.56, indicating a decrease of about 26.4%[16]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,856,866,778.45, a decrease of 1.27% from the end of the previous year[3]. - The company's total assets as of the end of Q3 2024 were CNY 3,856,866,778.45, slightly down from CNY 3,906,413,426.27 at the end of Q3 2023[16]. - Current liabilities increased to CNY 442,630,586.94 from CNY 363,869,054.38, reflecting an increase of approximately 21.6%[15]. - The company’s long-term liabilities decreased to CNY 127,237,259.14 from CNY 137,440,466.78, a reduction of approximately 7.9%[15]. - The total equity attributable to shareholders decreased by 3.47% to ¥3,286,998,932.37 compared to the end of the previous year[3]. - The total equity attributable to shareholders decreased to CNY 3,286,998,932.37 from CNY 3,405,103,905.11, a decline of approximately 3.5%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥96,620,500.57, reflecting a significant increase of 134.83% compared to the same period last year[6]. - Cash flow from operating activities for the first three quarters of 2024 was CNY 96,620,500.57, a recovery from a negative cash flow of CNY -277,430,186.77 in the same period last year[18]. - The company reported a net cash outflow from investing activities of CNY -631,706,261.31 in the first three quarters of 2024, compared to a smaller outflow of CNY -477,806,688.84 in the same period last year[19]. - The company’s cash flow from financing activities showed a net outflow of CNY -3,568,567.41 in Q3 2024, contrasting with a net inflow of CNY 198,652,069.31 in Q3 2023[19]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,236[8]. - The largest shareholder, Shaoxing Runkang Biological Pharmaceutical Equity Investment Partnership, holds 15,600,000 shares, accounting for 26.61% of the total shares[9]. - The company completed a share buyback of 1,949,918 shares, representing 3.33% of the total share capital, with a total expenditure of RMB 150.0163 million[11]. - The company plans to use between RMB 150 million and RMB 300 million for share repurchase within three months from the approval date[11]. - The highest repurchase price during the buyback was RMB 90.00 per share, while the lowest was RMB 69.70 per share[11]. - The company has no significant changes in the top 10 shareholders due to securities lending or borrowing activities[10]. - The company’s total share capital is 58,620,000 shares[9]. Cost Management - The company has implemented cost reduction and efficiency enhancement measures, which have positively impacted net profit growth[6][7]. - Total operating costs decreased significantly to CNY 308,029,355.80 from CNY 437,980,740.76, representing a reduction of approximately 29.6%[16]. Inventory and Receivables - The company is focusing on optimizing accounts receivable collection and inventory turnover management to improve financial performance[7]. - Accounts receivable decreased to RMB 59,908,099.69 from RMB 108,714,894.80, indicating a decline of about 44.9%[12]. - The company’s inventory increased to CNY 100,168,273.87 from CNY 93,859,936.04, reflecting an increase of about 6.9%[14]. Foreign Exchange and Other Gains - Non-recurring gains and losses for Q3 2024 amounted to ¥12,213,993.69, with government subsidies contributing ¥10,994,161.40[4]. - The company experienced a foreign exchange loss of CNY -6,501,055.88 in Q3 2024, compared to a gain of CNY 7,500,948.92 in the same period last year[17].